{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "EMT",
      "apoptosis",
      "bortezomib",
      "drug resistance",
      "epigenetic gene regulation"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "28028240",
  "DateCompleted": {
    "Year": "2018",
    "Month": "04",
    "Day": "09"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "11",
    "Day": "13"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2016",
        "Month": "12",
        "Day": "27"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1073/pnas.1619067114"
    ],
    "Journal": {
      "ISSN": "1091-6490",
      "JournalIssue": {
        "Volume": "114",
        "Issue": "2",
        "PubDate": {
          "Year": "2017",
          "Month": "Jan",
          "Day": "10"
        }
      },
      "Title": "Proceedings of the National Academy of Sciences of the United States of America",
      "ISOAbbreviation": "Proc Natl Acad Sci U S A"
    },
    "ArticleTitle": "Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.",
    "Pagination": {
      "StartPage": "382",
      "EndPage": "387",
      "MedlinePgn": "382-387"
    },
    "Abstract": {
      "AbstractText": [
        "The use of proteasome inhibitors to target cancer's dependence on altered protein homeostasis has been greatly limited by intrinsic and acquired resistance. Analyzing data from thousands of cancer lines and tumors, we find that those with suppressed expression of one or more 19S proteasome subunits show intrinsic proteasome inhibitor resistance. Moreover, such proteasome subunit suppression is associated with poor outcome in myeloma patients, where proteasome inhibitors are a mainstay of treatment. Beyond conferring resistance to proteasome inhibitors, proteasome subunit suppression also serves as a sentinel of a more global remodeling of the transcriptome. This remodeling produces a distinct gene signature and new vulnerabilities to the proapoptotic drug, ABT-263. This frequent, naturally arising imbalance in 19S regulatory complex composition is achieved through a variety of mechanisms, including DNA methylation, and marks the emergence of a heritably altered and therapeutically relevant state in diverse cancers."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142; petert@wi.mit.edu."
          }
        ],
        "LastName": "Tsvetkov",
        "ForeName": "Peter",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139."
          }
        ],
        "LastName": "Sokol",
        "ForeName": "Ethan",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139."
          }
        ],
        "LastName": "Jin",
        "ForeName": "Dexter",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142."
          }
        ],
        "LastName": "Brune",
        "ForeName": "Zarina",
        "Initials": "Z"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142."
          }
        ],
        "LastName": "Thiru",
        "ForeName": "Prathapan",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Broad Institute, Cambridge, MA 02142."
          }
        ],
        "LastName": "Ghandi",
        "ForeName": "Mahmoud",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Broad Institute, Cambridge, MA 02142."
          },
          {
            "Identifier": [],
            "Affiliation": "Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115."
          }
        ],
        "LastName": "Garraway",
        "ForeName": "Levi A",
        "Initials": "LA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139."
          },
          {
            "Identifier": [],
            "Affiliation": "Koch Institute for Integrative Cancer Research, Cambridge, MA 02139."
          },
          {
            "Identifier": [],
            "Affiliation": "Harvard Stem Cell Institute, Cambridge, MA 02138."
          }
        ],
        "LastName": "Gupta",
        "ForeName": "Piyush B",
        "Initials": "PB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115."
          }
        ],
        "LastName": "Santagata",
        "ForeName": "Sandro",
        "Initials": "S"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142."
          }
        ],
        "LastName": "Whitesell",
        "ForeName": "Luke",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142."
          },
          {
            "Identifier": [],
            "Affiliation": "Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139."
          },
          {
            "Identifier": [],
            "Affiliation": "Howard Hughes Medical Institute, Cambridge, MA 02139."
          }
        ],
        "LastName": "Lindquist",
        "ForeName": "Susan",
        "Initials": "S"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Proc Natl Acad Sci U S A",
    "NlmUniqueID": "7505876",
    "ISSNLinking": "0027-8424"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Proteasome Inhibitors"
    },
    {
      "RegistryNumber": "EC 3.4.25.1",
      "NameOfSubstance": "Proteasome Endopeptidase Complex"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Cell Line, Tumor"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "DNA Methylation"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Drug Resistance, Neoplasm"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug therapy",
        "metabolism"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Proteasome Endopeptidase Complex"
    },
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Proteasome Inhibitors"
    }
  ],
  "CoiStatement": "L.A.G. is a consultant for Foundation Medicine, Novartis, Boehringer Ingelheim, and Third Rock; an equity holder in Foundation Medicine; and a member of the Scientific Advisory Board at Warp Drive. L.A.G. receives sponsored research support from Novartis, Astellas, BMS, and Merck."
}